"Darbepoetin alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.
| Descriptor ID |
D000068256
|
| MeSH Number(s) |
D12.776.395.240.150.500
|
| Concept/Terms |
Darbepoetin alfa- Darbepoetin alfa
- Novel Erythropoiesis Stimulating Protein
- NESP
- Darbepoietin alfa
|
Below are MeSH descriptors whose meaning is more general than "Darbepoetin alfa".
Below are MeSH descriptors whose meaning is more specific than "Darbepoetin alfa".
This graph shows the total number of publications written about "Darbepoetin alfa" by people in this website by year, and whether "Darbepoetin alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Darbepoetin alfa" by people in Profiles.
-
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clin Exp Nephrol. 2023 Aug; 27(8):651-659.
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65.
-
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-Jun; 28(3B):1767-71.